Bone mass in Type 1 diabetes mellitus

Several recent studies suggest that diabetes mellitus is an underlying disease for secondary osteoporosis. Furthermore, the risk of fracture is increased in diabetic patients irrespective of their diabetic clinical type. The objective of this is study was to evaluate the bone mineral mass of children with Type 1 Diabetes Mellitus and compare them according to time of diagnosis, to observe the impact on bone mass gain. We designed a prospective longitudinal study with 33 patients between 04 and 20 years of age with at least one year of diagnosis of type 1 diabetes mellitus (DM1). It was performed at Hospital Materno Infantil de Brasília from April to August of 2009. The bone mineral densitometry was measured on all patients by DXA. They were separated into two groups by the time of diagnosis. One group with less than four years of diagnosis of DM1 (<4) and the other group with more than four years of disease (+4). There was a statistical difference between groups: When Z -score was compared, the <4 group had a mean z -score of -0,39, and the 4+ group had a mean z -score of 0,17(p=0,099). The <4 group had a mean Bone Mineral Content of 1062,27 grams, while the 4+ group had 1498,55 grams. (p=0,008). The diabetes metabolic control was worst in patients group with more recent diagnosis, with mean A1c of 9,11 mg/dL, and the group with the longer time of diagnosis presented a mean A1c of 8,51 mg/dL. This difference was not statistically significant (p=0,329) Conclusions: Patients with a better metabolic control presented a better bone mineral content than those with worst metabolic control. According to the literature, the poor metabolic control may be the cause of poor bone mass acquisition. Both groups didn’t have low bone mass, but it was observed a higher bone mass content on the group with better metabolic control. Correspondence to: Joao Lindolfo C Borges, Universidade Católica de Brasília, Centro de Pesquisa Clínica do Brasil, Brazil, Tel: 55 61 3364-1117, E-mail: [email protected] Received: September 15, 2016; Accepted: October 18, 2016; Published: October 21, 2016 Introduction Diabetes is a disease with a prevalence of 171 million people around the world in 2000, with a projection to rise to 366 million in 2030 [1]. Type 1 diabetes is increasing rapidly with an incidence, in 2009, 6666 of 3.4 million young people and a prevalence of 1.93 per 1000 in the United States [2]. It is characterized by destruction of beta cells and deregulation of alpha cells with micro and macrovascular complications. The pancreatic lesion is a very simplistic definition because this metabolic derangement can lead to repercussion in every single system, and most recently observed in the skeletal system. Several recent studies suggest that diabetes mellitus is an underlying disease for secondary osteoporosis. Furthermore, the risk of fracture is increased in diabetic patients irrespective of their diabetic clinical type [3]. Forsén et al. showed a prospective study with people of 50 years of age and older, attending a Health screening in Norwegian county. They were followed for nine years, and the authors investigated the incidence of hip fractures in this population. The study demonstrated that women with DM1 have a greater relative risk of hip fractures than the control group [4]. Nicodemus K et al. in 2001 performed a prospective study in postmenopausal women between 55 to 69 years of age. All fractures were registered by year, for 11 years. It was observed that women with DM1 were 12.25 times more likely to report an incident hip fracture than women without diabetes [5]. A more recent meta-analysis published in 2007 showed that BMD Z-scores of hip and spine in DM1 patients was lower than those nondiabetic participants [6]. There are many theories to support the decreased bone quality in diabetic patients: 1) Poor control of diabetes, keeping an hyperglycemic state leading to an excessive glycation of type 1 collagen changing the material properties of bone collagen [7,8]; 2) Suppressed bone turnover [9]; 3) Autoimmune inflammation [7]; 4) Hypoinsulinemia that leads to a suppression of osteoblast markers and a systemic or local Insulin Growth Factor-1 (IGF-1) deficiency [3,7,10]; 5) Action of other pancreatic hormones that plays a role in bone turnover [11]; 6) Low bone mass acquisition [12]. Studies showed that long-standing poor glycemic control was positively correlated with the presence of micro and macrovascular diabetic complications, and it might predict low BMD in patients with DM1. These include retinopathy, peripheral neuropathy, and nephropathy. Also, these complications may lead to a higher morbidity and limit physical activity, muscular and skeletal interactions and diminished visual acuity, enhancing the propensity of falls, as another risk factor for those patients [7,8]. Lopes FSC (2016) Bone mass in Type 1 diabetes mellitus Rheumatol Orthop Med, 2016 doi: 10.15761/ROM.1000101 Volume 1(1): 2-4 Valério G, et al., analyzed 27 adolescents with DM1 for at least six years of diagnosing. They found that the poor metabolic control might expose those patients to a higher risk of developing osteopenia in adult life [13]. There are other pathways to impair the bone turnover with poor metabolic control. Type I collagen is the main constituent protein of bone matrix. Its main function is to absorb tension and bone deformation. Previous findings have shown that advanced glycation end products (AGEs) may not support bone resorption properly and reduces bone resorption. Patients with osteoporosis have AGEs accumulated in all their tissues, and consequently, those glycated products may decrease the mechanical properties of cortical and trabecular bones, increasing the risk of fractures [9]. The collagen products as well as the factors for mineralization, which are secreted from mature osteoblasts, and the collagen degradation products derived from bone tissue resorption by osteoclasts are indices of bone turnover. It was observed that bone formation, as well as reabsorption markers, are significantly lower in diabetic patients [3]. Hypoinsulinemia leads to a suppression of osteoblast markers and generates a systemic and local IGF-1 deficiency. IGF-1 is an important factor in the bone matrix for promoting proliferation and differentiation of osteoblasts [3,7,10]. It was observed a low serum IGF-1 in female type 2 diabetes. This finding is related to an increased risk of vertebral fractures independent of Bone mineral density. Also, IGF-1 serum levels were positively correlated with indices of bone formation, as procollagen type I, propeptides, alkaline phosphatase and osteocalcin, in subjects with DM1, but not in healthy controls. A study conducted in more than 100 children and young adults with DM1 showed that IGF-1 serum levels and biochemical markers of bone formation such as osteocalcin were lower in patients with DM1 compared with healthy subjects [7]. There is a hypothesis that the autoimmune process itself, characterized by the presence of activated T cells and associated with osteoclastogenic cytokine microenvironment, including increased RANKL, is involved in impaired bone metabolism in patients with DM1, even before clinical symptoms of the disease [7]. Pancreatic and enteric hormones have an important role in bone turnover regulation. Glucagon-like polypeptide 2 (GLP-2) receptors are located on osteoclasts, and it was demonstrated that administration of physiological doses of GLP-2 reduced bone resorption. Gastric Inhibitory Peptide (GIP) receptors are located on osteoblasts. Activation of GIP receptors was shown to enhance expression of alkaline phosphatase and the secretion of type I collagen. Therefore, both hormones seem to have osteotropic effects [11]. Almost 90% of bone mass is gained in the first 20 years of life. An important way of preventing osteoporosis and fractures later in life is to optimize peak bone mass and bone strength. Also, most of the DM1 patients have their onset of the disease before achieving their peak of bone mass. Consequently, the diabetic patient has a higher risk of low bone mass in youth, osteopenia and osteoporosis precociously in their lives [12]. Furthermore, because osteoporosis is a multifactorial skeletal disease, the link between BMD and the risk factors may be hardly understandable. The major point is to demonstrate when the bone metabolism starts to work deficiently on those patients [8]. Materials and methods The study is a prospective longitudinal study with 33 patients between 04 and 20 years of age with at least one year of diagnosis of DM1. They were chosen randomly in the Diabetes regular clinical appointments at Hospital Materno Infantil de Brasília between April of 2009 and August of the same year. The study was performed after approval by the ethical committee of the FEPECS, Brasilia. A written informed consent was obtained from all patients and their parents after the full discussion about the aim of the study. The inclusion criteria were: patients with at least four years of age and with maximum 20 years of age, with at least one year of diagnosing of type 1 diabetes. The exclusion criteria of the study were: Type 2 diabetes, any cancer, thyroid disorders, growth hormone deficiency, genetic syndromes, vitamin D deficiency, hypogonadism, chronic use of glucocorticoids, rheumatologic diseases, hepatic, renal and cardiologic diseases unrelated to diabetes, transplant patients, pregnant patients or patients with BMI greater than 95 percentiles. They were submitted to complete physical exam: weight (kg), Height (m), BMI (kg/m2), arterial blood pressure (mmHg), pubertal evaluation (Tanner method), evaluation of neuropathies (sensibility tests) and research of lipodystrophies. A questionnaire was made about the disease: time of diagnosis, insulin types and dosing, previous hospitalizations. And other questions involved assessment of bone mineral metabolism: calcium intake (considered suitable as more than 2 portions a day); sun exposure evaluated as minutes per day (considered as 30 minutes/ day as suitable); physical activity according to hours per week (h/w) of exercise (as less than 3 h/w and 3h/w or more); The bone mineral densitometry was performed on all patients by dual energy X-ray absorptiometry, DXA, pediatric software, GE-Lunar, Prodigy. They were evaluated by z-score, bone mineral content, body composition, according to gender, age, ethnic group, weight and height and body surface. They were also submitted to biochemical tests: hemoglobin glycated (A1c), serum and 24-hour urinary calcium, phosphorus, magnesium, sodium, potassium, chlorine, 24 h microalbuminuria. The patient’s medical history was assessed to evaluate the retrospective metabolic control of the subjects. All statistical analyses were performed by comparison of means of two independent samples and by Pearson correlation coefficient. The software used was SPSS version 17.